Alector Q3 net income swings to $124.6 million
- Alector swung to third-quarter 2026 net income of $124.6 million from a year-earlier net loss of $34.7 million.
- Collaboration revenue rose to $162.9 million, primarily due to recognition of remaining deferred revenue following GSK's termination notice.
- An exclusive global AL050 license agreement with Genentech provides $100 million upfront and up to $1.17 billion in milestone payments.
- Lead Alzheimer's program AL137 targets first-in-human dosing in Australia no later than April 2027.
- Cash resources, the Genentech upfront payment and offering proceeds are expected to fund operations into the second half of 2029.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alector Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611051605PRIMZONEFULLFEED9870694) on November 05, 2026, and is solely responsible for the information contained therein.